PMID- 28835680
OWN - NLM
STAT- MEDLINE
DCOM- 20180207
LR  - 20181113
IS  - 1476-5470 (Electronic)
IS  - 1466-4879 (Linking)
VI  - 18
IP  - 3
DP  - 2017 Sep
TI  - Transcriptome analysis of ankylosing spondylitis patients before and after TNF-alpha 
      inhibitor therapy reveals the pathways affected.
PG  - 184-190
LID - 10.1038/gene.2017.19 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) inhibitors are highly effective in suppressing 
      inflammation in ankylosing spondylitis (AS) patients, and operate by suppression 
      of TFN-alpha and downstream immunological pathways. To determine the mechanisms of 
      action of TNF-alpha inhibitors in AS patients, we used transcriptomic and 
      bioinformatic approaches on peripheral blood mononuclear cells from AS patients 
      pre and post treatment. We found 656 differentially expressed genes, including 
      the genome-wide significant AS-associated genes, IL6R, NOTCH1, IL10, CXCR2 and 
      TNFRSF1A. A distinctive gene expression profile was found between male and female 
      patients, mainly because of sex chromosome-linked genes and interleukin 17 
      receptor C, potentially accounting for the differences in clinical manifestation 
      and treatment response between the genders. In addition to immune and 
      inflammation regulatory pathways, like intestinal immune network for IgA 
      production, cytokine-cytokine receptor interaction, Ras signaling pathway, 
      allograft rejection and hematopoietic cell lineage, KEGG (Kyoto Encyclopedia of 
      Genes and Genomes) pathway analyses revealed that infection-associated pathways 
      (influenza A and toxoplasmosis) and metabolism-associated pathways were involved 
      in response to TNF-alpha inhibitor treatment, providing insight into the mechanism of 
      TNF-alpha inhibitors.
FAU - Wang, X B
AU  - Wang XB
AD  - Rheumatology Department, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Ellis, J J
AU  - Ellis JJ
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Pennisi, D J
AU  - Pennisi DJ
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Song, X
AU  - Song X
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Batra, J
AU  - Batra J
AD  - Cancer and Molecular Medicine Program, School of Biomedical Sciences, Institute 
      of Health and Biomedical Innovation, Queensland University of Technology (QUT), 
      Brisbane, Queensland, Australia.
AD  - Australian Prostate Cancer Research Centre-Queensland, Translational Research 
      Institute, Woolloongabba, Queensland, Australia.
FAU - Hollis, K
AU  - Hollis K
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Bradbury, L A
AU  - Bradbury LA
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Li, Z
AU  - Li Z
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Kenna, T J
AU  - Kenna TJ
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
FAU - Brown, M A
AU  - Brown MA
AD  - Institute of Health and Biomedical Innovation, School of Biomedical Sciences, 
      Queensland University of Technology (QUT) at Translational Research Institute, 
      Brisbane, Australia.
AD  - Centre for Precision Medicine, The First Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170824
PL  - England
TA  - Genes Immun
JT  - Genes and immunity
JID - 100953417
RN  - 0 (IL10 protein, human)
RN  - 0 (IL6R protein, human)
RN  - 0 (NOTCH1 protein, human)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Receptors, Interleukin-6)
RN  - 0 (Receptors, Interleukin-8B)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (TNFRSF1A protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
SB  - IM
MH  - Adult
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Interleukin-10/genetics/metabolism
MH  - Male
MH  - Middle Aged
MH  - Receptor, Notch1/genetics/metabolism
MH  - Receptors, Interleukin-6/genetics/metabolism
MH  - Receptors, Interleukin-8B/genetics/metabolism
MH  - Receptors, Tumor Necrosis Factor, Type I/genetics/metabolism
MH  - Spondylitis, Ankylosing/drug therapy/*genetics/metabolism
MH  - *Transcriptome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2017/08/25 06:00
MHDA- 2018/02/08 06:00
CRDT- 2017/08/25 06:00
PHST- 2017/03/25 00:00 [received]
PHST- 2017/06/06 00:00 [revised]
PHST- 2017/06/07 00:00 [accepted]
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2018/02/08 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
AID - gene201719 [pii]
AID - 10.1038/gene.2017.19 [doi]
PST - ppublish
SO  - Genes Immun. 2017 Sep;18(3):184-190. doi: 10.1038/gene.2017.19. Epub 2017 Aug 24.